Whereas in the NAPC group, compared to pre-NAPC, post-NAPC CD20+ B cells, CD4+ T cells, CD8+ T cells, CD8+CD127+ T cells, and CD8+KLRG1+ T cells were significantly elevated in MPR, but not in non-MPR patients (Fig. 4a, b), suggesting that the co-increase of these subpopulations could coordinate and interplay with each other to promote anti-tumor immune responses. This evidence concerns the gene CD8A and neoplasm.